TP53 and non-small cell lung carcinoma: In the present study, we show that low dose RV treatment leads to a significant increase in senescence-associated β–galactosidase (SA-β-gal) staining and elevated p53 and p21 expression in NSCLC cells, suggesting that the anticancer effect of RV is largely attributable to the induction of senescence in lung cancer cells.